Methods of treating protozoal diseases

US6506393B2 · kind B2 · utility

Assignees

• Zentaris GmbH · DE
• Max-Planck-Gesellschaft zur Föderung der Wissenschaften e.V. · US

Inventors

• Hansjorg Eibl · Bovenden, DE
• Clemens Unger · Göttingen, DE
• Jurgen Engel · Alzenau, DE

Key dates

• Filing date: Mar 7, 2001
• Grant date: Jan 14, 2003
• Expiry date: Mar 31, 2021

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention concerns a new pharmaceutical agent for oral or topical administration in the treatment of protozoal diseases, in particular of leishmaniasis, which contains as the active substance one or several compounds having the general formula I in which R1 is a saturated or monounsaturated or polyunsaturated hydrocarbon residue with 12 to 20 C atoms and R2, R3 and R4 denote independently of one another hydrogen, a C1-C5 alkyl group, a C3-C6 cycloalkyl group or a C1-C5 hydroxyalkyl group whereby two of the residues R2, R3 and R4 can together form a C2-C5 alkylene group which, if desired, can be substituted with an —O—, —S— or NR5 group, in which R5 is hydrogen, a C1-C5 alkyl group, a C3-C6 cycloalkyl group or a C1-C5 hydroxyalkyl group as well as, if desired the usual pharmaceutical auxiliary, diluting, carrier or/and filling substances.